Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cruise stocks are taking on water Monday after the Centers for Disease Control and Prevention (CDC) dashed hopes for sailing to resume sooner than expected. Source: Shutterstock.com Cruise companies were pushing for...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Humanigen (NASDAQ: HGEN ) stock are taking off on Monday morning after the firm reported major news for those suffering from the novel coronavirus. Source: luchschenF / Shutterstock.com The biopharma...
Universe Pharmaceuticals (UPC) +113%.Humanigen (HGEN) +61% on positive Phase 3 data for COVID-19 therapy.Cyanotech Corporation (CYAN) +48%.Big Rock Partners Acquisition (BRPA) +42%.SeaChange International (SEAC) +34% on multi-million-dollar contract with broadband service provider.F...
Humanigen (HGEN) has added ~43.8% in the pre-market after announcing that its lead drug candidate against COVID-19, lenzilumab achieved the primary endpoint in a Phase 3 study in patients who were hospitalized with COVID-19 pneumonia.In the randomized trial, the patients w...
Lenzilumab improved the relative likelihood of survival without need for invasive mechanical ventilation (IMV) by 54%, achieving the primary endpoint of the Phase 3 study Clinical improvement was observed over and above other treatments, including steroids and/or remdesivir ...
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, announced that management will host a confer...
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, announced today that its board of di...
The following slide deck was published by Humanigen, Inc. in conjunction with this event. For further details see: Humanigen (HGEN) Presents At Oppenheimer 31st Annual Healthcare Conference - Slideshow
Humanigen (HGEN): Q4 GAAP EPS of -$0.63 beats by $0.04.Revenue of $312kCash and cash equivalents of $67.7MPress Release For further details see: Humanigen EPS beats by $0.04
Humanigen (HGEN) has obtained a term loan facility from Hercules Capital (HTGC) for up to $80M of secured debt financing.“The term loan facility provides working capital to support the production of lenzilumab, strengthens our balance sheet and increases our financial flexibility as we...
News, Short Squeeze, Breakout and More Instantly...
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...